PHIO PHARMACEUTICALS CORP. - COMMON STOCK

Phio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO)

30 4月 2024 06:30:00 条件 Nasdaq GlobeNewswire

Intratumoral Injection of Phio’s PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells

22 4月 2024 12:10:09 条件 Nasdaq GlobeNewswire

Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)

16 4月 2024 06:30:00 条件 Nasdaq GlobeNewswire

Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)

11 4月 2024 06:30:00 条件 Nasdaq GlobeNewswire

National Spotlight Features Phio’s Innovative RNAi Technology Platform

03 4月 2024 06:30:00 条件 Nasdaq GlobeNewswire

Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update

02 4月 2024 06:30:00 条件 Nasdaq GlobeNewswire

Phio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies

21 3月 2024 06:30:00 条件 Nasdaq GlobeNewswire

Phio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity Research

13 3月 2024 13:00:25 条件 Nasdaq GlobeNewswire

Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Treating Aging Skin and Skin Disorders

06 3月 2024 09:30:59 条件 Nasdaq GlobeNewswire

Phio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies

31 1月 2024 07:00:00 条件 Nasdaq GlobeNewswire

Phio Pharmaceuticals Announces Exercise of Warrants for $2.8 Million Gross Proceeds

07 12月 2023 07:00:00 条件 Nasdaq GlobeNewswire

Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

09 11月 2023 15:30:20 条件 Nasdaq GlobeNewswire

Phio Pharmaceuticals Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas

09 11月 2023 06:30:00 条件 Nasdaq GlobeNewswire

Phio Pharmaceuticals Presents New Data Showing INTASYL Compound targeting CTLA-4 Enhances Tumor Control

03 11月 2023 11:00:00 条件 Nasdaq GlobeNewswire

Phio Pharmaceuticals Announces Upcoming Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

12 10月 2023 10:00:00 条件 Nasdaq GlobeNewswire

Phio Pharmaceuticals Presents New Data for Targeting of BRD4 with its INTASYL™ Compound PH-894

11 10月 2023 06:30:19 条件 Nasdaq GlobeNewswire

Phio CEO to Speak at Wainwright Conference in New York in September

06 9月 2023 06:30:00 条件 Nasdaq GlobeNewswire

Phio Pharmaceuticals Announces Dosing of First Patient in Collaborative Clinical Trial with AgonOx, Inc. and Providence Cancer Institute

21 8月 2023 06:30:53 条件 Nasdaq GlobeNewswire

Phio Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

10 8月 2023 15:30:19 条件 Nasdaq GlobeNewswire